Amneal Pharma Stock Rises On FDA Approval For Generic Version Of AbbVie’s Eyedrops
Synopsis
Amneal’s bimatoprost ophthalmic solution 0.01% is indicated for the reduction of high eye pressure in patients with certain eye conditions.
Amneal Pharmaceuticals (AMRX) said on Tuesday that its generic equivalent of AbbVie's (ABBV) eyedrops received approval from the U.S. Food and Drug Administration.
The company’s Bimatoprost ophthalmic solution 0.01% is indicated for reducing high eye pressure in patients with open-angle glaucoma or ocular hypertension. It is a generic equivalent of LUMIGAN 0.01%, whose design is a trademark of AbbVie’s Allergan.
Shares of the company rose 5% in the pre-market session at the time of writing.
Get updates to this developing story <directly on Stocktwits.<
Stay updated with all the latest Business News, including market trends, Share Market News, stock updates, taxation, IPOs, banking, finance, real estate, savings, and investments. Track daily Gold Price changes, updates on DA Hike, and the latest developments on the 8th Pay Commission. Get in-depth analysis, expert opinions, and real-time updates to make informed financial decisions. Download the Asianet News Official App from the Android Play Store and iPhone App Store to stay ahead in business.